Menu Search
Equities

Clearside Biomedical Inc

CLM:FRA

Clearside Biomedical Inc

Actions
  • Price (EUR)0.98
  • Today's Change0.025 / 2.62%
  • Shares traded3.00k
  • 1 Year change+12.00%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 14:51 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.

  • Revenue in USD (TTM)7.70m
  • Net income in USD-31.88m
  • Incorporated2011
  • Employees30.00
  • Location
    Clearside Biomedical Inc900 North Point Parkway, Suite 200ALPHARETTA 30005United StatesUSA
  • Phone+1 (678) 270-3631
  • Fax+1 (678) 270-4033
  • Websitehttps://clearsidebio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.